Navigation Links
RiversEdge BioVentures LLC to Provide Advisory and Investment Services in Life Sciences
Date:9/10/2009

The formation of RiversEdge BioVentures LLC is announced today by Principal and Founder, David A. Dodd.

Beaufort, SC (Vocus) - The formation of RiversEdge BioVentures LLC is announced today by Principal and Founder, David A. Dodd.

Prior to forming RiversEdge BioVentures LLC, Mr. Dodd achieved a highly distinguished career, serving in executive positions in several major pharmaceutical and life sciences companies.

Recently, Mr. Dodd served as President, CEO and Chairman of BioReliance Corporation, as an equity partner with Avista Capital Partners in establishing that organization as a stand-alone company following its purchase from Invitrogen Corporation (now, Life Technology, Inc.).

In addition, Mr. Dodd served as the non-executive Chairman of Stem Cell Sciences Plc. (LSE:AIM STEM; ASX: STC), leading a strategic transformation and eventual sale of that company to Stem Cells Inc. in April, 2009. Mr. Dodd also served on the Board of Stheno Corporation, a private life sciences technology company.

From June 2000 to July 2006, Mr. Dodd served as President, CEO and Director of Serologicals Corporation (NASDAQ: SERO), until the sale of Serologicals to Millipore Corporation (NYSE: MIL) in July, 2006.

From August 1995 until June 2000, he served as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc., and as a member of the Management Board for the Pharmaceutical Sector for Solvay S.A. Mr. Dodd also served as Chairman of the Board of Unimed Pharmaceuticals, Inc., a subsidiary of Solvay Pharmaceuticals. Prior to joining Solvay, he served in a number of management and executive positions with major life science corporations, including Wyeth, Bristol-Myers Squibb, and Abbott Laboratories.

Mr. Dodd holds a Bachelor of Science and Master of Science from Georgia State University and completed the Harvard Business School Advanced Management Program.

Contacts:
Kathryn Gallagher
RiversEdge BioVentures LLC
843.576.9840

Scott Litherland
Parallax Communications Group
317.335.7898

# # #

Read the full story at http://www.prweb.com/releases/2009/09/prweb2857834.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
2. Newbridge Securities Corporation Forms BioVentures Division
3. Apex Bioventures Acquisition Corporation Receives Notice of Extension from NYSE Amex
4. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
5. CardioDynamics Provides 2007 Shareholder Meeting Update
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
7. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
8. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
9. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
10. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
11. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics ... Awards. uBiome is one of just six company finalists in the Health & ... to uBiome, companies nominated as finalists in this year’s awards include Google, SpaceX, ...
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. ... company focused on developing and commercializing products to treat ... announced today that it will be hosting an Investor ... ET on the origins of innate defense regulators (IDRs) ... review of oral mucositis and the recently announced and ...
(Date:12/8/2016)... SEOUL, South Korea , Dec. 8, 2016 /PRNewswire/ ... completed a $21 billion KRW (US $18.9M) Series A ... Management, Kolon Investment, G.N. Tech Venture and SNU Bio ... by Eutilex to 30.5 billion KRW (US $27.7M) since ... will help Eutilex to bolster the development and commercialization ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. presented ... expansion clinical trial for its lead drug candidate, AC0010, at the World Conference ... was to determine the safety, antitumor activity, and recommended phase II dosage of ...
Breaking Biology Technology:
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/15/2016)... Md. , Nov. 15, 2016  Synthetic ... company developing therapeutics focused on the gut microbiome, ... offering of 25,000,000 shares of its common stock ... common stock at a price to the public ... proceeds to Synthetic Biologics from the offering, excluding ...
(Date:6/22/2016)... American College of Medical Genetics and Genomics was once again ... of the fastest-growing trade shows during the Fastest 50 Awards ... Las Vegas . Winners are ... of the following categories: net square feet of paid exhibit ... 2015 ACMG Annual Meeting was ranked 23 out of 50 ...
Breaking Biology News(10 mins):